A small company can now advance its psychedelic into Phase 3. Here’s why
that matters to other psychedelic biotechs.
-
GH Research’s stock rallied after saying the FDA lifted a hold on its
experimental depression treatment.
45 minutes ago
Posts
No comments:
Post a Comment